A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Condition: Colo-rectal Cancer Interventions: Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluorouracil; Biological: Bevacizumab; Drug: Irinotecan; Biological: Cetuximab; Procedure: Metastasectomy; Procedure: Biospecimen collection Sponsor: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials